Company Encyclopedia
View More
name
Simulations Plus
SLP.US
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals; and DDDPlus and MembranePlus simulation products.
64.63 B
SLP.USMarket value -Rank by Market Cap -/-

Financial Score

14/12/2025 Update
C
Health Care TechnologyIndustry
Industry Ranking15/44
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-42.13%E
    • Profit Margin-81.74%E
    • Gross Margin58.38%B
  • Growth ScoreC
    • Revenue YoY13.09%B
    • Net Profit YoY-750.17%E
    • Total Assets YoY-32.90%E
    • Net Assets YoY-31.59%E
  • Cash ScoreC
    • Cash Flow Margin-122.34%D
    • OCF YoY13.09%B
  • Operating ScoreC
    • Turnover0.48C
  • Debt ScoreA
    • Gearing Ratio5.41%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Simulations Plus (NASDAQ:SLP) Updates FY 2026 Earnings Guidance

    Simulations Plus (NASDAQ:SLP) updated its FY 2026 earnings guidance, projecting EPS of 1.030-1.100, above the consensus estimate of 1.010. Revenue guidance is set at $79.0 million-$82.0 million, compared to the consensus of $79.6 million. Analysts have mixed ratings on SLP, with an average rating of "Hold" and a target price of $24.40. The stock opened at $19.80, with a market cap of $398.97 million. Institutional investors hold 78.08% of the stock.

    Market Beat·
    US
    SLP
    -1.74%
    Market Beat·
    US
    SLP
    -1.74%

    Simulations Plus (SLP) to benefit from FDA's streamlined nonclinical safety guidance with advanced solutions.

    Simulations Plus, Inc. (Nasdaq: SLP), a key player in model-informed and AI-accelerated drug development globally, has addressed the recent draft guidance from the U.S. Food and Drug Administration (FDA) regarding streamlined nonclinical safety studies for monospecific monoclonal antibodies. This guidance aims to decrease dependence on animal trials and enhance mechanistic comprehension and pharmacokinetic understanding. Simulations Plus, known for its innovations in biopharma, is responding to this initiative, emphasizing a shift towards advanced approaches in drug development.

    Unusual Whales·
    US
    SLP
    -1.74%
    Unusual Whales·
    US
    SLP
    -1.74%

    Simulations Plus Announces New Executive Appointments

    Simulations Plus has announced new executive appointments. The announcement lacks specific details about the company's industry or products. Analyst ratings for SLP stock are mixed, with a Hold rating and a $20.50 price target. Financial performance challenges include declining revenue and profitability, despite short-term technical strength. The market cap is $395.6M, with a trading volume of 520,095. Technical sentiment signals a Sell.

    Tip Ranks·
    US
    SLP
    -1.74%
    Tip Ranks·
    US
    SLP
    -1.74%

    Simulations Plus Positioned to Capitalize on FDA’s Streamlined Nonclinical Safety Guidance with Advanced Mechanistic and Model-Informed Solutions | SLP Stock News

    Simulations Plus, Inc. is poised to capitalize on the FDA's draft guidance for streamlined nonclinical safety studies, emphasizing mechanistic and model-informed approaches. The company aligns its AI-driven ecosystem with FDA's regulatory framework, enhancing drug development processes. Simulations Plus aims to support clients in integrating physiologically based pharmacokinetics and mechanistic insights, fostering growth in underpenetrated areas. The FDA's guidance opens new opportunities for Simulations Plus in model-informed safety and toxicology disciplines.

    StockTitan·
    US
    SLP
    -1.74%
    StockTitan·
    US
    SLP
    -1.74%

    Simulations Plus Updates Executive Compensation Agreements

    Simulations Plus Inc. has updated employment agreements for key executives, including CEO Shawn O’Connor and CFO Will Frederick. Frederick's new agreement includes a $359,100 base salary, a 35% cash bonus, and 20,000 stock options. Jill Fiedler-Kelly's agreement offers a one-time payment and COBRA benefits if terminated without cause. This AI-generated brief is for informational purposes only.

    Reuters·
    US
    SLP
    -1.74%
    Reuters·
    US
    SLP
    -1.74%
    © 2025 Longbridge｜Disclaimer